Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19

Abstract Background The emergence and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in thelate 2019 has caused a devastating global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19). Although vaccines have been and are being developed, t...

Descrición completa

Detalles Bibliográficos

Principais autores:	Maral Aminpour, Williams Ernesto Miranda Delgado, Soren Wacker, Sergey Noskov, Michael Houghton, D. Lorne J. Tyrrell, Jack A. Tuszynski
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2021-10-01
Series:	BMC Pharmacology and Toxicology
Assuntos:	COVID-19 Toxicity Repurposing drugs, hERG)
Acceso en liña:	https://doi.org/10.1186/s40360-021-00519-5
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!